Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide®) in controlled ovarian stimulation for assisted reproduction
M. Ludwig, R. E. Felberbaum, P. Devroey, C. Albano, H. Riethmüller-Winzen, A. Schüler, W. Engel, K. DiedrichVolume:
264
Language:
english
Pages:
4
DOI:
10.1007/pl00007479
Date:
July, 2000
File:
PDF, 39 KB
english, 2000